The New Drug Application (NDA) number 018644 refers to Wellbutrin [1]. This designation signifies the submission and review process by the U.S. Food and Drug Administration (FDA) for the approval of the drug [1].
What is Wellbutrin approved for?
Wellbutrin, also known by its generic name bupropion, is an antidepressant medication [2]. It is approved for the treatment of major depressive disorder and seasonal affective disorder [2]. Bupropion is also used in some formulations to aid in smoking cessation [3].
When does Wellbutrin's patent expire?
Information regarding the specific patent expiry dates for Wellbutrin can be found through specialized databases. DrugPatentWatch.com provides comprehensive patent information for pharmaceuticals, including expiry timelines [4]. The patent landscape for any drug is complex and can involve multiple patents covering different aspects of the drug's composition, formulation, and method of use [4].
Can generic versions of Wellbutrin be made?
Generic versions of Wellbutrin are available [2]. The availability of generic alternatives typically follows the expiration of relevant patents and exclusivity periods granted by regulatory agencies [4]. Once these protections expire, other manufacturers can seek approval to market generic versions of the drug, often leading to lower prices [4].
How does bupropion work?
Bupropion's exact mechanism of action is not fully understood, but it is believed to affect neurotransmitters in the brain, primarily norepinephrine and dopamine [2]. Unlike some other antidepressants, it has minimal effects on serotonin [2]. This distinct mechanism may contribute to its efficacy in certain patient populations and its different side effect profile compared to selective serotonin reuptake inhibitors (SSRIs) [2].
What are the risks and side effects of Wellbutrin?
Common side effects of Wellbutrin can include dry mouth, insomnia, nausea, vomiting, agitation, headache, and tremor [2]. A significant risk associated with bupropion is a potential for seizures, especially at higher doses or in individuals with predisposing factors [2][3]. The drug also carries a boxed warning regarding increased suicidal thoughts and behaviors in children, adolescents, and young adults [2].
---
Sources:
[1] U.S. Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from fda.gov
[2] National Alliance on Mental Illness. (n.d.). Bupropion. Retrieved from nami.org
[3] U.S. National Library of Medicine. (n.d.). Bupropion. Retrieved from medlineplus.gov
[4] DrugPatentWatch.com. (n.d.). Retrieved from drugpatentwatch.com